new molecules and indications for glp-1 medicines Emerging Frontiers in Therapeutics: A Comprehensive Evidence Base (2025) What is the pipeline for

Tirzepatide can push that number even higher

Long-Acting Formulations Many GLP-1 Agonists are available in long-acting formulations, which means they only need to be taken once a week

Sarcopenia, or age-related muscle loss, can lead to decreased physical function, increased risk of falls and fractures, higher susceptibility to chronic diseases, and negative impacts on mental health if left unaddressed

There are more than 70 million Americans currently enrolled in Medicare, 10 million of whom are overweight or obese, according to Juliette Cubanski, vice president and director of the program on Medicare policy at the healthcare research nonprofit KFF

Not necessarily a big concern, but if a potential treatment or cause for this can be discovered, I presume that would be helpful

doi: 10.1038/nm1010-1097